In This Article:
NAPLES, FL / ACCESSWIRE / September 4, 2024 / ("STEK") Stemtech Corporation, the pioneer and trailblazer in the stem cell nutrition sector, is proud to announce that OTC Markets has approved us to quote as an OTCQB stock, symbolizing a commitment to transparency and investor confidence. As we consolidate our footprint in the United States, Mexico, Ecuador, Canada and Taiwan, this milestone is a testament to our dedication to global health through groundbreaking stem cell nutrition, skin care, oral care and as recently announced on August 22, pet care technologies.
The global stem cells market is poised for substantial growth, projected to increase from $14.92 billion in 2023 to $49.26 billion by 2034, with a compound annual growth rate of 11.47%. This growth underscores the expanding opportunities within the sector, driven by innovations in regenerative medicine and increasing application across therapeutic areas.
Stemtech Chairman and CEO, Charles S. Arnold states "with the passage of time, there is an enhanced awareness, and more people are becoming educated about the power, the miracle of stem cells and the benefits of helping your body help itself. Our niche products are reasonably priced, and our life-maintenance system is something everyone should be taking to improve their quality of life".
With decades of research and development, Stemtech is the knowledge leader in the stem cell nutrition industry. Our expertise spans the development of products that naturally enhance the body's ability to renew and repair itself, using scientifically validated approaches that underscore our commitment to quality, efficacy, and safety.
At Stemtech, our focus remains on enhancing human and soon pet health by harnessing the potential of all-natural, plant-based stem cell products, offering solutions that not only meet current health challenges but also anticipate future needs. Join us as we lead the charge in a revolution to naturally enhance anti-aging, longevity, and quality of life worldwide. This, combined with our income-earning business opportunity makes Stemtech a very attractive model for health and wealth.
ABOUT STEMTECH
Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech products. Stemtech is well positioned as the pioneer in stem cell nutrition, oral, skin care and soon pet health products, to increase sales in the wellness industry.